|Year : 2015 | Volume
| Issue : 5 | Page : 176-180
Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity
Qian Li1, Yanyang Tu2
1 Department of Experimental Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China
2 Department of Experimental Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, China
|Date of Submission||16-Apr-2015|
|Date of Acceptance||14-Aug-2015|
|Date of Web Publication||29-Oct-2015|
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Source of Support: None, Conflict of Interest: None
Glioblastoma multiforme (GBM) is a heterogeneous group of tumors, each with its own distinct molecular and genetic signatures. This heterogeneity is a major clinical hurdle for classifying tumors and for devising effective personalized therapies targeting the disease pathways. Herein, the primary genetic and epigenetic alterations in GBM that have been used as therapeutic targets in clinical settings nowadays, with or without clinical benefits for patients, as well as the future directions for developing novel strategies were discussed.
Keywords: Glioblastoma multiforme, molecular profiling, targeted therapy
|How to cite this article:|
Li Q, Tu Y. Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity. Cancer Transl Med 2015;1:176-80
| Introduction|| |
Glioblastoma multiforme (GBM) is the most common and fatal adult brain tumor, accounting for 60–70% of all gliomas. Despite the advances in the treatment options, the median survival time for patients with GBM is approximately 15 months. GBM is divided into primary and secondary glioblastoma based on their clinical characteristics. The primary glioblastoma progresses rapidly and has an absence of precursor lesions while secondary glioblastoma progresses as diffuse astrocytoma (WHO Grade II) or anaplastic astrocytoma (WHO Grade III).,, Recent investigations on genetic profile of GBM have revealed some "single biomarkers" useful in diagnostic and prognostic assessments, such as isocitrate dehydrogenase-1 (IDH1) mutations, which are frequently detected in secondary glioblastoma (> 80%) but are rare in primary glioblastoma (< 5%).,,,, The Cancer Genome Atlas More Details (TCGA) research described a molecular classification of GBM, based on its gene expression, into proneural, neural, classical, and mesenchymal subtypes  and also updated the knowledge of distinct genomic alterations between primary and secondary glioblastoma [Table 1].
|Table 1: The distinct genetic and clinical characteristics between primary and secondary glioblastoma|
Click here to view
| Molecular Heterogeneity|| |
Recently, the comprehensive large-scale genomic analyses have identified intratumoral heterogeneity of GBM to further refine the histopathological classification of this disease. The TCGA have shown genetic and epigenetic alterations in GBM and revealed its potential prognostic or diagnostic biomarkers such as TP53 mutation, IDH1 mutation, epidermal growth factor receptor (EGFR) amplification/mutation, and O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation.,
Intratumoral molecular heterogeneity is a clinical and therapeutical challenge in fighting tumor recurrence and invasion. To understand this challenge, we can look at the two extensively used targeted therapies: Targeting EGFR or vascular endothelial growth factor inhibitors. Such targeted therapies end up affecting a subpopulation of tumor cells that actively express the respective proteins but do not influence the rest of the tumor cells which continue to proliferate through a selection phase. Gene expression profiling has shown distinct molecular and genetic aberrations involved in tumorigenesis ,, of GBM and is subclassified accordingly to match the standard subclassification. Verhaak et al. proposed four molecular subtypes featuring distinct genetic, epigenetic, and transcriptional alterations, including proneural, neural, classical, and mesenchymal, which are accepted for their prognostic and diagnostic value. The examples of such molecular subtypes are IDH1/2 mutation for proneural, EGFR amplification for classical and neurofibromin 1 (NF1) loss for mesenchymal. EGFR amplification, IDH1/2 mutations, and hypermethylation of the promoter of the MGMT gene, together with co-deletion of 1p and 19q serve as the primary detection biomarkers.
| Molecular Biomarkers|| |
Epidermal growth factor receptor amplification/variants
EGFR is the most common therapeutic target in glioblastoma with the prevalence of its gene amplification in 40–60% of patients.,, EGFR alterations subsequently activate multiple cell signaling pathways and ultimately accelerates tumor growth and progression. The most common EGFR mutant variant is EGFRvIII, which is a constitutive activation of EGFR in a ligand-independent way and has a controversial prognostic impact. EGFRvIII variant has been found not related to patient outcome, associated with unfavorable prognosis, or as a molecular predictor for prolonged overall survival. The attempts to block EGFR signaling by small molecule inhibitors, such as erlotinib and gefitinib, or monoclonal antibodies could not get the desired results, even after molecular preselection of patients. Accordingly, the mechanisms underlying resistance to EGFR-targeted therapies and prognostic value of EGFR amplification or its variants remain to be clarified.
Isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mutations
Both IDH1 and IDH2 mutations are more frequently detected among Grade II to III gliomas and secondary glioblastoma (70–75%), whereas they are rare in primary glioblastoma (5%)., IDH1 mutations are strongly associated with TP53 mutation and deletion of 1p/19q. IDH1 mutations are typically present in younger patients with TP53 mutations and are associated with a better outcome. IDH1/2 mutations are also strongly associated with epigenetic alterations., IDH mutation together with 1p/19q co-deletion and glioma-CpG island hypermethylator phenotype (G-CIMP) are recognized as the prognostic criterion of a favorable outcome and also as a predictor of chemotherapy response.,
O(6)-Methylguanine-DNA methyltransferase promoter methylation
MGMT encodes a DNA repair enzyme involved in repairing the cytotoxic adducts produced by alkylating chemotherapy using temozolomide. Hypermethylation or epigenetic silencing of MGMT disables DNA repair capacity and render tumor cells more sensitive to treatment. MGMT promoter methylation is a common feature in IDH1/2 mutant/G-CIMP positive glioma; however, it is less prevalent in G-CIMP negative tumors, such as primary glioblastoma.,,
Neurofibromin 1 loss
NF1 gene encodes NF1, which is a tumor suppressor and negatively regulates RAS and mammalian target of rapamycin (mTOR) signaling in astrocytomas.,, NF1 mutations are the most common characteristics of mesenchymal GBM subtype. Inactivation of NF1 protein may arise from increased degradation, mediated by hyperactivation of protein kinase C., NF1 loss could cause increased cell proliferation and migration through hyperactivation of mTOR, mediated by RAS signaling pathway, in NF1-deficient primary murine astrocytes. Although the homozygous loss of NF1 results in increased cell growth, both under in vitro and in vivo conditions, it alone is inadequate for inducing tumor formation in genetically engineered mouse models. Several studies, using genetically engineered mouse models, have shown that the homozygous loss of NF1 in glial cells results in malignant astrocytomas when associated with a TP53 mutation  and further progress to GBM when combined with phosphatase and tensin homologue deletion.
Platelet-derived growth factor receptor alpha amplification
Platelet-derived growth factor receptor alpha (PDGFRA) gene is amplified in approximately 13% of GBMs, mainly in a proneural subtype of GBM., Amplification of PDGF and PDGFR is proved to be associated with aggressive glioma growth. PDGFR and/or its ligands expression lead to tumor development through both autocrine and paracrine signaling mechanisms., In addition, PDGFR can also be activated in the absence of its ligand. An intragenic deletion in PDGFRA, termed PDGFRA Δ,, is found to be associated with increased downstream c-Jun phosphorylation in a ligand-independent manner. Point mutations are detected exclusively in Grade IV gliomas, which suggests that PDGFRA-targeted therapy could be a promising therapeutic target for these patients.
| Clinical Implications of Heterogeneity|| |
Intratumoral heterogeneity serves two purposes in clinical settings: One as a prognostic and predictive biomarker to guide personalized treatments, and the other as a failure factor in targeted therapies. Among genetic alterations in GBM, majority exists in three signaling pathways including RTK/RAS/PI3K, p53/MDM2/MDM4, and RB/CDK4/INK4A. Several common targeted treatments in clinical trials are shown in [Table 2]. However, targeted agents such as bevacizumab have shown minimal efficacy in clinical trials and overall survival compared to the current standard of care remain poor., The combination of diversity of tumor subclones, poor drug penetration, and activation of other compensatory pathways contribute to this failure.,
In conclusion, identification of subtypes and novel markers such as IDH1 are promising addition to traditional histopathological grading for improving prognostic and predictive ability. However, because of the limitations in diagnostic approaches added with the complex changes during tumor progression, the response to therapy may not be intrinsically predictable, yet. The concept of personalized treatment to meet the clinical needs is still a long way to go. The combined treatment with multiple inhibitors of different pathways or treatments using agents targeting the regulatory molecules may be a promising future direction for a successful GBM treatment.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol
2005; 109 (1): 93–108.
Peiffer J, Kleihues P. Hans-Joachim Scherer (1906-1945), pioneer in glioma research. Brain Pathol
1999; 9 (2): 241–5.
Scherer HJ. Cerebral astrocytomas and their derivatives. Am J Cancer
1940; 40: 159–98.
Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, Bao Z, Zhang W, You Y, Jiang T. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget
2014; 5 (24): 12908–15.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol
2008; 116 (6): 597–602.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol
2009; 174 (4): 1149–53.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med
2009; 360 (8): 765–73.
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res
2009; 15 (19): 6002–7.
Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd
, Yan H, Bigner DD. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget
2014; 5 (6): 1515–25.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell
2010; 17 (1): 98–110.
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res
2004; 64 (19): 6892–9.
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature
2008; 455 (7216): 1061–8.
Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res
2011; 71 (12): 4055–60.
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell
2006; 9 (3): 157–73.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network. Identification of a CpG Island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell
2010; 17 (5): 510–22.
Zheng S, Chheda MG, Verhaak RG. Studying a complex tumor: potential and pitfalls. Cancer J
2012; 18 (1): 107–14.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol
2007; 114 (2): 97–109.
Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs
2012; 21 (9): 1247–66.
Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res
2005; 11 (4): 1462–6.
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd
, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol
2007; 25 (16): 2288–94.
Montano N, Cenci T, Martini M, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia
2011; 13 (12): 1113–21.
Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol
2012; 25 (6): 774–9.
Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J
2013; 280 (21): 5350–70.
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1and IDH1 mutations refine the classification of malignant gliomas. Oncotarget
2012; 3 (7): 709–22.
Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol
2011; 12 (1): 83–91.
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol
2009; 27 (34): 5743–50.
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol
2013; 31 (3): 337–43.
van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol
2013; 31 (3): 344–50.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell
2013; 155 (2): 462–77.
Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer
2009; 101 (1): 124–31.
Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol
2010; 12 (2): 116–21.
Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol
2014; 10 (7): 372–85.
Banerjee S, Crouse NR, Emnett RJ, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci U S A
2011; 108 (38): 15996–6001.
Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res
2014; 74 (8): 2340–50.
Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res
2005; 65 (1): 236–45.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature
2008; 455 (7216): 1061–8.
McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell
2009; 16 (1): 44–54.
Sandsmark DK, Zhang H, Hegedus B, Pelletier CL, Weber JD, Gutmann DH. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res
2007; 67 (10): 4790–9.
Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol
2002; 22 (14): 5100–13.
Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell
2005; 8 (2): 119–30.
Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, Mason RP, Lee EY, Wu H, Parada LF. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res
2008; 68 (9): 3286–94.
Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci
2006; 26 (25): 6781–90.
Assanah MC, Bruce JN, Suzuki SO, Chen A, Goldman JE, Canoll P. PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain. Glia
2009; 57 (16): 1835–47.
Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene
2003; 22 (5): 722–33.
Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussière M, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. Neuro Oncol
2012; 14 (11): 1393–403.
Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balaña C, Gil M, Gallardo A, Murata P, Barnadas A. Efficacy of erlotinib in patients with relapsed gliobastomamultiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. J Neurooncol
2014; 116 (2): 413–9.
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiformepostradiation therapy. Neuro Oncol
2010; 12 (1): 95–103.
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol
2010; 12 (10): 1061–70.
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol
2009; 27 (8): 1268–74.
Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys
2013; 85 (5): 1206–11.
Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys
2011; 80 (2): 347–53.
Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol
2009; 92 (1): 99–105.
Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L, Brandes AA. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer
2007; 96 (7): 1047–51.
Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA; New Approaches to Brain Tumor Therapy Consortium. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol
2013; 15 (4): 490–6.
Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a North Central Cancer Treatment Group trial. Clin Cancer Res
2013; 19 (17): 4816–23.
Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol
2012; 14 (12): 1511–8.
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd
, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol
2011; 101 (1): 57–66.
Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol
2010; 96 (3): 393–402.
Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer
2009; 101 (12): 1995–2004.
See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1deficiency. Cancer Res
2012; 72 (13): 3350–9.
Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr Biol
2008; 18 (1): 56–62.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med
2014; 370 (8): 709–22.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med
2014; 370 (8): 699–708.
Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol
2012; 355: 135–69.
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol
2014; 16 (4): 567–78.
[Table 1], [Table 2]
|This article has been cited by|
||Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles
| ||Zeming Chen,Fuyao Liu,Yanke Chen,Jun Liu,Xiaoying Wang,Ann T. Chen,Gang Deng,Hongyi Zhang,Jie Liu,Zhangyong Hong,Jiangbing Zhou |
| ||Advanced Functional Materials. 2017; : 1703036 |
|[Pubmed] | [DOI]|
||Acylglycerol kinase functions as an oncogene and an unfavorable prognostic marker of human gliomas
| ||Nan Liu,Zhen Wang,Yingduan Cheng,Pengxing Zhang,Xin Wang,Hongwei Yang,Hui Liu,Yongsheng Zhang,Yanyang Tu |
| ||Human Pathology. 2016; |
|[Pubmed] | [DOI]|